Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 15;19(3):2269794.
doi: 10.1080/21645515.2023.2269794. Epub 2023 Oct 26.

Research trends on immunotherapy for pancreatic cancer: A bibliometric analysis

Jubao Niu  1 , Wenkai Jiang  1 , Dongao Fan  1 , Xin Li  1 , Wence Zhou  1   2 , Hui Zhang  1   2
Affiliations

Research trends on immunotherapy for pancreatic cancer: A bibliometric analysis

Jubao Niu et al. Hum Vaccin Immunother. .

Abstract

This study aims to summarize and visually analyze the current research status in pancreatic cancer immunotherapy during the past two decades by bibliometrics and explore the current research hotspots and future development directions. The literature related to pancreatic cancer immunotherapy from 2002 to 2021 was downloaded from the core database of the Web of Science. VOSviewer and CiteSpace software were used to visualize the included literature. A total of 2528 articles were included. In the past two decades, publications in the pancreatic cancer immunotherapy field have increased almost annually. As the country with the largest publications, the United States has various research institutions dedicated to pancreatic cancer immunotherapy. Jaffee EM and Zheng L from Johns Hopkins University and Vonderheide RH from the University of Pennsylvania have published the most articles in this field. The current research hotspots of pancreatic cancer immunotherapy include the tumor microenvironment, immune cells, immune checkpoint blockade, and combination therapy. The study of novel immunotherapies and combination therapy may become the primary focus of future research on pancreatic cancer immunotherapy. More prospective clinical studies with high evidence levels should be conducted.

Keywords: Pancreatic cancer; bibliometrics; immunotherapy; visual analysis.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Flow chart of literature screening.
Figure 2.
Figure 2.
Trends of pancreatic cancer immunotherapy publications over the past 20 years.
Figure 3.
Figure 3.
Top 10 countries/regions and institutions related to pancreatic cancer immunotherapy from 2002 to 2021.
Figure 4.
Figure 4.
Country/region cooperation network.
Figure 5.
Figure 5.
Density map of the authors in the area of immunotherapy for pancreatic cancer.
Figure 6.
Figure 6.
Co-occurrence network map of keywords.
Figure 7.
Figure 7.
CiteSpace visualization map of burstiness of keywords.
Figure 8.
Figure 8.
Some treatment targets in the tumor microenviroment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493–12. PMID: 34002083. doi:10.1038/s41575-021-00457-x. - DOI - PMC - PubMed
    1. Chen X, Yi B, Liu Z, Zou H, Zhou J, Zhang Z, Xiong L, Wen Y. Global, regional and national burden of pancreatic cancer, 1990 to 2017: results from the global burden of disease study 2017. Pancreatology. 2020;20(3):462–9. PMID: 32113937. doi: 10.1016/j.pan.2020.02.011. - DOI - PubMed
    1. Collaborators GBD Pancreatic Cancer . The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934–47. PMID: 32061329. doi:10.1016/S2468-1253(20)30018-2. - DOI - PMC - PubMed
    1. Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer. 2018;4(6):418–28. PMID: 29860986. doi:10.1016/j.trecan.2018.04.001. - DOI - PMC - PubMed
    1. Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17–35. PMID: 31940268. doi:10.1016/j.immuni.2019.12.011. - DOI - PubMed

Publication types